Xenon Pharmaceuticals Inc. — Director's Dealing 2021

Jun 3, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Xenon Pharmaceuticals Inc. (XENE)
CIK: 0001582313
Period of Report: 2021-06-03

Reporting Person: AULIN SHERRY (Chief Financial Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-06-03	Stock Option (Right to Buy)	$18.56	A	100000	Acquired	2031-06-02	Common Shares (100000)	Direct

Footnotes

F1: Vesting 25% on the one year anniversary of the grant date, and 75% vesting thereafter over the course of the next 3 years, in equal amounts, on
the last day of each month.